Monday, May 2, 2016 5:02:00 AM PDT | VentureDeal
Gaithersburg, Maryland -- Biotechnology company Sirnaomics has secured $10 million in new equity venture capital financing, according to an SEC regulatory filing.
Sirnaomics is utilizing RNA interference technology to develop targeted therapeutics for serious human diseases. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. Sirnaomics is still seeking $2.5 million in additional financing, according to the filing. President and CEO Patrick Lu has been with the firm since March 2007.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
